Scientific Foundation
Rooted in validated academic research from one of the world's leading medical institutions.
Anaxa's research originates from studies conducted at a leading medical university focusing on immune mechanisms and Biomarker 143 in sarcoidosis.
At a leading medical university in Sweden, a research group in translational immunology set out to answer a fundamental question: Could sarcoidosis be identified through a simple blood-based biomarker?
Through analysis of extensive patient cohorts, Biomarker 143 was identified as being associated with sarcoidosis.
Focus on immune responses in respiratory system
Identification of Biomarker 143
Studies across large patient cohorts
Confirmed using bead-based assays and ELISA
Key Discovery
A distinct immunological signal that could transform sarcoidosis diagnosis.
Through extensive analysis of patient samples, a distinct immunological signal emerged. Biomarker 143 was found to be significantly elevated in patients with sarcoidosis.
This pattern was not observed in healthy controls or related diseases, suggesting a specific association with sarcoidosis that could form the basis of a diagnostic test.
The findings have been confirmed using multiple analytical platforms, including bead-based assays and ELISA, demonstrating reproducibility across different laboratory methodologies.
Research Focus
Understanding the role of dendritic cells and monocytes in pulmonary inflammatory diseases, with a focus on how immune responses develop in sarcoidosis.
Identifying biomarkers that may predict disease severity, progression, and inform better treatment strategies for patients with sarcoidosis.
Translating research findings into practical diagnostic tools that can be integrated into standard clinical laboratory workflows.
Working with clinical samples and patient cohorts to validate findings and ensure reliability across diverse patient populations.
Learn how we're translating these research findings into a practical diagnostic approach for sarcoidosis.